- Home
- ORN vs BSX Comparison
ORN vs BSX Comparison
Compare ORN & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORN
- BSX
- Stock Information
- Founded
- ORN 1994
- BSX 1979
- Country
- ORN United States
- BSX United States
- Employees
- ORN N/A
- BSX N/A
- Industry
- ORN Military/Government/Technical
- BSX Medical/Dental Instruments
- Sector
- ORN Industrials
- BSX Health Care
- Exchange
- ORN Nasdaq
- BSX Nasdaq
- Market Cap
- ORN N/A
- BSX 138.4B
- IPO Year
- ORN 2007
- BSX 1992
- Fundamental
- Price
- ORN $6.33
- BSX $102.73
- Analyst Decision
- ORN Strong Buy
- BSX Strong Buy
- Analyst Count
- ORN 3
- BSX 23
- Target Price
- ORN $12.50
- BSX $110.57
- AVG Volume (30 Days)
- ORN 305.6K
- BSX 10.3M
- Earning Date
- ORN 04-29-2025
- BSX 04-23-2025
- Dividend Yield
- ORN N/A
- BSX N/A
- EPS Growth
- ORN N/A
- BSX 15.23
- EPS
- ORN N/A
- BSX 1.37
- Revenue
- ORN $796,394,000.00
- BSX $17,554,000,000.00
- Revenue This Year
- ORN $3.55
- BSX $15.77
- Revenue Next Year
- ORN $11.66
- BSX $10.33
- P/E Ratio
- ORN N/A
- BSX $75.05
- Revenue Growth
- ORN 11.89
- BSX 19.36
- 52 Week Low
- ORN $4.64
- BSX $70.97
- 52 Week High
- ORN $12.12
- BSX $107.17
- Technical
- Relative Strength Index (RSI)
- ORN 61.37
- BSX 61.22
- Support Level
- ORN $5.68
- BSX $92.70
- Resistance Level
- ORN $6.30
- BSX $102.37
- Average True Range (ATR)
- ORN 0.32
- BSX 2.95
- MACD
- ORN 0.11
- BSX 1.17
- Stochastic Oscillator
- ORN 96.38
- BSX 97.14
About BSX Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.